GET THE FULL COMPANY
ANALYSIS BUNDLE FOR
Myriad
Who owns Myriad Genetics today?
The company shifted from patent monopoly to precision-medicine competitor after Paul Diaz became CEO in 2020, driving a multi-year transformation. Founded in 1991 from University of Utah research, Myriad focuses on predictive genetic testing and oncology diagnostics.
As of early 2025 Myriad is a mid-cap public company with market cap near $2.0 billion, 2024 revenue above $825 million, and substantial institutional ownership concentrated among mutual funds and ETFs; see Myriad Porter's Five Forces Analysis.
Who Founded Myriad?
Founded in May 1991, Myriad Genetics' early ownership combined academic IP from the University of Utah with venture capital leadership from Avalon Ventures, anchored by founders Dr. Mark Skolnick, Dr. Peter Meldrum, Dr. Walter Gilbert, and Kevin Kinsella.
Founding team roles
Dr. Skolnick supplied core genetic research; Dr. Gilbert brought scientific prestige; Kinsella provided VC expertise; Meldrum contributed operational leadership.
Initial capital structure
Avalon Ventures and the University of Utah research foundation held large early stakes in exchange for capital and exclusive licensing rights to BRCA discoveries.
Equity distribution
Early filings show founders and initial backers retained majority control through the first four years, though exact 1991 percentages remain proprietary.
IP and vesting
Strict intellectual property agreements and vesting schedules were used to keep the scientific team intact during the BRCA sequencing race.
Patent-driven ownership
Aggressive patenting created de facto ownership over genetic sequences, later subject to legal and public challenge in the 2000s.
Investor dilution
Early angels and friends-and-family investors saw dilution during Series A/B rounds as institutional investors increased stakes ahead of IPO preparations.
By IPO, the company structure favored institutional growth over individual founder retention, setting the stage for public ownership and eventual shifts in major shareholders; see Growth Strategy of Myriad for a focused review.
Key early ownership facts
Founders and founding investors shaped Myriad Company ownership and company structure through licensed university IP and venture capital backing.
- Founded May 1991 by Skolnick, Meldrum, Gilbert, and Kinsella
- 1991–1995: Majority control held by founders plus Avalon Ventures and University of Utah research foundation
- Early IP licensing gave university research foundation significant equity in exchange for BRCA rights
- Angel stakes were diluted in Series A/B as institutional investors prepared the company for IPO
Complete Myriad Strategy Bundle
- 6 Full Frameworks, 1 Company – All Pre-Researched
- Each Framework Fully Sourced with Real Company Data
- Built for Strategy Courses, Case Studies & MBA Programs
- Adapt to Your Assignment – No Starting from Scratch
- 6 Frameworks: SWOT, PESTLE, Porter's, BMC, BCG and 4P's
How Has Myriad’s Ownership Changed Over Time?
Key events reshaping Myriad Company ownership include the IPO on October 6, 1995, the steady transfer of founder and venture-capital stakes to institutional investors, major portfolio reallocations by index funds in the 2010s, and strategic shifts toward volume-driven diagnostics platforms that attracted passive holders and healthcare-focused asset managers.
| Event / Period | Impact on Ownership | Notable Outcome |
|---|---|---|
| 1995 IPO (NASDAQ: MYGN) | Raised approximately $45,000,000; founders & VCs retained large stakes | Market cap set expectations for genomics growth |
| 2000s–2010s Institutional accumulation | Gradual transfer to mutual funds, pension funds, and healthcare specialists | Increased emphasis on quarterly performance and cost efficiency |
| 2015–2025 Strategic product focus | Shift from patent-driven margins to scale-oriented testing revenue | Institutional ownership estimated at 96% by 2025 |
By Q1 2025 the shareholder register is dominated by index and active institutional owners, reshaping Myriad Company ownership, governance priorities, and capital allocation toward expanding GeneSight and MyRisk platforms.
Major 2025 Stakeholders
Top institutional holders concentrate voting power and influence strategic direction; their stakes are documented in SEC Schedule 13G/13F filings.
- The Vanguard Group — approximate stake 11.5%
- BlackRock Inc. — approximate stake 9.2%
- Neuberger Berman Group LLC — approximate stake 7.5%
- State Street Corporation — approximate stake 5.8%
Institutional dominance affects questions like 'Who owns Myriad' and 'Myriad company structure', concentrating influence but also exposing the company to passive-investor votes, activist interest, and performance-linked capital flows; see related analysis in Marketing Strategy of Myriad.
From PESTLE Factors to Full Strategy Bundle
- PESTLE + SWOT + Porter's + BCG + BMC + 4P's in One Bundle
- Every Strategic Angle Covered – Nothing Left to Research
- Pre-filled with Company-Specific Research
- No Missing Sections for Your Case Study
- One Download Covers Your Entire Company Analysis
Who Sits on Myriad’s Board?
The Myriad Genetics board was refreshed between 2022–2025 to support its Transformation 2.0 agenda; Dan Kimbrell chairs the board and Paul Diaz serves as CEO and director, joined by independent directors experienced in managed care, digital health, and clinical diagnostics.
| Director | Role / Background | Notes |
|---|---|---|
| Dan Kimbrell | Chair; corporate governance, payer strategy | Leads board refresh aligned to Transformation 2.0 |
| Paul Diaz | CEO & Director; executive leadership | Executive director with operational oversight |
| Independent Directors | Managed care, digital health, diagnostics | Includes former executives from major payers and pharma |
The board composition emphasizes alignment with the broader healthcare ecosystem rather than solely laboratory science, supporting strategic decisions across commercialization, payer engagement, and clinical partnerships.
Board structure and voting power
The company uses a one-share-one-vote structure with no dual-class shares or golden shares, making institutional holders influential and requiring transparency on targets and compensation.
- One-share-one-vote: no dual-class structure
- Institutional investors push for 10%–12% annual revenue growth targets for 2025–2026
- No major proxy contests in 2024, but ongoing shareholder engagement on GAAP profitability path
- Board refresh (2022–2025) focused on payer and digital-health expertise to support revenue and margin goals
Public shareholders and institutional blocks collectively determine control; as of year-end 2025 filings, the top 10 institutional owners hold approximately 35%–45% of outstanding shares, underscoring the importance of investor relations and consistent performance to retain support—see the company’s governance history in the Brief History of Myriad.
Myriad Business Model + Strategy Bundle
- Ideal for Essays, Case Studies & Slides
- Get BCG, SWOT, PESTLE, Porter's, 4P's Mix & BMC Together
- Company-Specific Content Already Organized
- One Bundle Replaces Days of Independent Research
- Buy the Bundle Once. Use Across All Your Assignments
What Recent Changes Have Shaped Myriad’s Ownership Landscape?
From 2022–2025 Myriad Company ownership shifted as management streamlined operations toward Oncology, Women’s Health and Mental Health, completing divestitures of non-core assets and attracting growth-focused institutional investors; strategic share buybacks in 2024 and rising ESG allocations altered the ownership mix.
| Ownership Category | Estimated Share (%) | Notable 2022–2025 Changes |
|---|---|---|
| Institutions | 62% | Net inflows from growth-oriented funds; active share repurchases in 2024 |
| ESG-focused funds | 12% | Increase tied to health-equity initiatives and expanded access programs |
| Insiders & Management | 6% | Stable holdings; management signaled confidence via buybacks |
| Retail & Others | 20% | Retail interest grew modestly after portfolio simplification |
The portfolio pruning (including the sale of international operations and Myriad RBM) and the 2023–2025 emphasis on pharmacogenomics and targeted diagnostics led to clearer Myriad company structure and improved operating focus, making the firm both an acquirer (Gateway Genomics) and a plausible takeover target amid anticipated industry consolidation.
Divestiture impact
Sales of non-core units reduced revenue volatility and concentrated R&D spend on oncology and pharmacogenomics pathways.
Share repurchases
2024 buybacks signaled management belief that the stock was undervalued; repurchases reduced float and increased institutional ownership influence.
ESG ownership trend
ESG funds now represent an estimated 12% of institutions, driven by initiatives to expand genetic testing access in underserved communities.
Near-term outlook
Public remarks at the 2025 JP Morgan Healthcare Conference emphasize independence pursuit as cash flow turns positive; however, high institutional ownership means a takeover premium could rapidly alter who owns Myriad.
For context on competitors and how consolidation may affect Myriad Group ownership and Myriad Genetics ownership dynamics see Competitors Landscape of Myriad
From Five Forces to Full Company Analysis
- Includes SWOT, PESTLE, BMC, BCG and 4P's
- Pre-Researched with Company-Specific Data
- Best Value for a Complete Analysis
- Ready to Adapt for Your Case Study
- Ready for Essays and Slidesd
- What is Brief History of Myriad Company?
- What is Competitive Landscape of Myriad Company?
- What is Growth Strategy and Future Prospects of Myriad Company?
- How Does Myriad Company Work?
- What is Sales and Marketing Strategy of Myriad Company?
- What are Mission Vision & Core Values of Myriad Company?
- What is Customer Demographics and Target Market of Myriad Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.